Chinese biopharmaceutical company RemeGen Co., Ltd. (SHA:688331, HKG:09995) announced on Friday that it has received clearance from the United States Food and Drug Administration to initiate Phase II clinical trials for its bispecific antibody RC148.
RC148 is a novel bispecific antibody designed for the treatment of multiple advanced malignant solid tumours targeting both PD-1 and VEGF. It was developed using RemeGen's proprietary bispecific antibody technology platform.
Clinical trials for RC148, both as a monotherapy and in combination treatments, are currently ongoing in China.
FDA approval to proceed with US trials represents a major milestone in RC148's global clinical development strategy.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA